DENISE GOODWIN: Open Payments
NPI 1407377831 · FORT OGLETHORPE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,763 in 86 payments from 14 companies in 2025. Trend: 2023 $1,642 · 2024 $1,861 · 2025 $1,763
Food & beverage: $1,763
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 15 | $426 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $285 |
| Supernus Pharmaceuticals, Inc. | 13 | $254 |
| ABBVIE INC. | 14 | $186 |
| Teva Pharmaceuticals USA, Inc. | 7 | $146 |
| Alkermes, Inc. | 4 | $93 |
| Lundbeck LLC | 3 | $81 |
| Axsome Therapeutics, Inc. | 4 | $78 |
| Corium, LLC | 5 | $68 |
| Janssen Pharmaceuticals, Inc | 2 | $56 |
Products named: INGREZZA, CAPLYTA, Qelbree, VRAYLAR, UZEDY, REXULTI, Auvelity, ARISTADA.
Industry payments across GA — which companies pay providers there.
